The CagriSema phase 2 paper and what a fixed combination buys — the long version

The CagriSema phase 2 paper and what a fixed combination buys — the long version Writing it up because I had to work it out twice and would rather nobody else did.

A narrow question about CagriSema phase 2 paper, deliberately narrow, because the broad version has been asked here four times and produced four long threads and no answer.

One question, stated units, stated method, and what I have already ruled out.

I would be cautious about generalising from the CagriSema phase 2 paper example above. It is a good example. It is one example.

On CagriSema phase 2 paper the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.

On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.

The interesting part of this is the exception, and I do not understand the exception.

Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.

I would treat the number as indicative rather than as a measurement.

Adding the measurement that post #55 says would settle it.

Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.

The general case is well covered; this is the awkward specific one.

The phase 3 combination programme is where the clinically interesting numbers will come from. Phase 2 established that the combination does something; the size of it in a larger population is a separate question.

The strength of my opinion here exceeds the strength of my evidence.

Reading the phase 2 paper: it establishes tolerability and efficacy in a selected population on a defined dose escalation. It does not establish the lowest effective dose or the durability over years.

I have said this before in a thread nobody could find, so it is worth repeating.

Where I part company with post #149, and it is a narrow parting.

Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.